Gashenko et al. found significantly increased levels of procathepsin B, cystatin B (CstB), and Cst3 in serum and ascite fluids of ovarian cancer patients compared to controls, suggesting their possible use as disease biomarkers [211]. This evidence concerns the gene CST3 and ovarian cancer.